⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20602606 | 0.64 | MEN1 (0.32) | — | |
| SCHEMBL2187322 | 0.64 | — | — | |
| SCHEMBL7547068 | 0.64 | — | — | |
| SCHEMBL3019925 | 0.62 | PDPK1 (0.39) | — | |
| SCHEMBL1438685 | 0.57 | — | — | |
| SCHEMBL10677362 | 0.56 | — | — | |
| SCHEMBL3022168 | 0.56 | ALDH1A1 (0.35) | — | |
| SCHEMBL238844 | 0.56 | — | — | |
| SCHEMBL368186 | 0.56 | — | — | |
| SCHEMBL12604725 | 0.55 | PDPK1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | claimed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | claimed |
| US-20100311787-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1809294-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-08-06 | — | — | EP | claimed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | claimed |
| US-4794120-A | BACTERICIDES, FUNGICIDES | SYNTHELABO (FR) | 1988-12-27 | — | — | US | claimed |
| EP-3740206-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11918592-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-5124453-A | Treatment of corresponding aldehyde with lithium bis(tri-methylsilyl)amide | E. R. SQUIBB & SONS, INC. (US) | 1992-06-23 | — | — | US | disclosed |
| US-4794120-A | BACTERICIDES, FUNGICIDES | SYNTHELABO (FR) | 1988-12-27 | — | — | US | disclosed |